Interim analysis of the phase 3 JAVELIN Bladder 100 trial showed that maintenance therapy with the PD-L1 inhibitor Bavencio (avelumab) plus best supportive care significantly prolonged survival compared with the current best supportive care alone in patients with advanced urothelial carcinoma, the most common type of bladder cancer, that did not progress (get worse) after treatment with first-line platinum-based chemotherapy.
Patients with extensive-stage small-cell lung cancer, a rare type of lung cancer, now have a new first-line treatment option with Imfinzi (durvalumab), a PD-L1 inhibitor, in combination with chemotherapy, according to new results presented at the 2020 ASCO annual meeting. This new combination has been shown to improve survival for these patients, who do not have many treatment options and whose prognosis (survival outlook) is less than 5 years.
Treatment with the PD-1 inhibitor Keytruda (permbrolizumab) significantly extended progression-free survival (PFS) in patients with classical Hodgkin lymphoma compared with standard treatment with Adcetris (brentuximab vedotin), according to the results of the phase 3 KEYNOTE-204 clinical trial reported at the ASCO 2020 virtual annual meeting.
About 15% of lung cancers are small-cell lung cancer, and about one-third of those are extensive-stage small-cell lung cancer. In March 2020, the FDA approved the first immunotherapy, for use with chemotherapy, for first-line treatment of patients with extensive-stage small-cell lung cancer.
This article discusses findings from a clinical trial showing that Keytruda prolongs the time without disease progression in patients with relapsed or refractory classical Hodgkin lymphoma compared with the current standard of therapy.
“This therapy is an innovative approach, one that combines the precision of a targeted, immune-based therapy with traditional myeloma therapy. The results are very encouraging, giving renewed hope to patients who have relapsed,” says ASCO President-Elect Julie M. Vose, MD, MBA, Chief of the Division of Oncology/Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha.
Last modified: September 24, 2017
Subscribe to CONQUER™: the patient voice™ magazine
Receive timely cancer news & updates, patient stories, and more.